AEternaZentaris Inc. (USA)(NASDAQ:AEZS) Marches Forward


Dallas, Texas 02/26/2014 (Financialstrend) – AEternaZentaris Inc. (USA)(NASDAQ:AEZS) as the late-stage drug developer for some of the most infectious diseases has  a market capital of $57.77million. The P E for this company is 4.54 and the average trading price varies between $1.28 low and high of $1.30. The 52 week high for this drug maker is $2.67, while the low is $0.99. the company also holds EPS of 0.28, while BETA is 1.77.

In its latest news, the company has since declared that the results of its cancer drug for treating the endometrium are now to be available for peer review. The Phase 2 results for zoptarelin Doxorubicin are to be available in the Feb issue of Journal of GynecologicalCancer .

AEternaZentaris Inc. (USA)(NASDAQ:AEZS) is a Quebec based Canadian company engaged in development of late-stage drugs which are directed at such diseases as oncology as well as endocrine. The drugs which this AEternaZentaris Inc. (USA)(NASDAQ:AEZS) leading developer is able to provide include those compounds which are different development stages. Besides, the company has also been a committed players in marketing of its products as well. Currently, the development priorities have been the oncology as well as the Phase 3 trials. These are known to help in treating such cancers as Colorectal cancer as well as Multiple myeloma.

AEternaZentaris Inc. (USA)(NASDAQ:AEZS) has also been successful in bringing higher value due to the AEZA-108 compound. In fact, this drug has already completed it Phase 2 trial and is also found to have endured advanced endometrial as well as cancer of the ovaries. The company will also work on another compound which is the AEZS-112, an oral anticancer agent.

For AEternaZentaris Inc. (USA)(NASDAQ:AEZS) this is also believed to deliver such solutions as the Oral anticancer agents.It works on three mechanisms. The drug is found to be using strengths to fight he likes of tubulin, topoisomerase II as well as the angiogenesis inhibition. The phase 1 trial has already been completed for solid tumors as well as lymphoma.